Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$2.19 USD
-0.21 (-8.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Werewolf Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -37.37 | -53.81 | -49.98 | -15.04 | -10.25 |
Depreciation/Amortization & Depletion | 1.82 | 1.31 | 0.22 | 0.15 | 0.03 |
Net Change from Assets/Liabilities | -5.89 | 2.54 | 2.28 | 2.31 | -0.71 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.83 | 9.37 | 4.61 | -6.04 | 1.39 |
Net Cash From Operating Activities | -32.61 | -40.60 | -42.88 | -18.62 | -9.54 |
Property & Equipment | -0.77 | -3.61 | -0.50 | -0.56 | -0.27 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.77 | -3.61 | -0.50 | -0.56 | -0.27 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 18.43 | 16.45 | 111.81 | 94.20 | 22.10 |
Issuance (Repayment) of Debt | 40.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -0.54 | -2.38 | -0.34 | -0.19 |
Net Cash from Financing Activities | 58.43 | 15.91 | 109.43 | 93.86 | 21.91 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 25.05 | -28.30 | 66.05 | 74.67 | 12.10 |
Cash at Beginning of Period | 130.53 | 158.83 | 92.78 | 18.10 | 6.00 |
Cash at End of Period | 155.58 | 130.53 | 158.83 | 92.78 | 18.10 |
Diluted Net EPS | -1.05 | -1.86 | -10.94 | -28.09 | NA |
Fiscal Year End for Werewolf Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -33.44 | -16.19 | -37.37 | -25.37 | -17.08 |
Depreciation/Amortization & Depletion | 0.92 | 0.46 | 1.82 | 1.36 | 0.92 |
Net Change from Assets/Liabilities | -1.75 | -2.34 | -5.89 | -10.52 | -8.43 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.80 | 2.77 | 8.83 | 6.50 | 3.78 |
Net Cash From Operating Activities | -29.47 | -15.30 | -32.61 | -28.03 | -20.82 |
Property & Equipment | -0.13 | -0.11 | -0.77 | -0.57 | -0.35 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.13 | -0.11 | -0.77 | -0.57 | -0.35 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 21.21 | 20.26 | 18.43 | 9.50 | 9.44 |
Issuance (Repayment) of Debt | -10.00 | 0.00 | 40.00 | 40.00 | 40.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.67 | 0.00 | 0.00 | -0.14 | -0.12 |
Net Cash from Financing Activities | 10.54 | 20.26 | 58.43 | 49.36 | 49.32 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -19.06 | 4.85 | 25.05 | 20.76 | 28.15 |
Cash at Beginning of Period | 155.58 | 155.58 | 130.53 | 130.53 | 130.53 |
Cash at End of Period | 136.51 | 160.43 | 155.58 | 151.29 | 158.68 |
Diluted Net EPS | -0.43 | -0.39 | -0.34 | -0.23 | -0.14 |